() (OTC:PDDPF) CEO Ken d’Entremont tells Proactive Investors that Health Canada has authorized the Montreal-based specialty pharma company to distribute Treosulfan through the special access program.
Treosulfana is a conditioning agent used before stem cell transplantation.
The company will look to bring Treosulfann to the US, according to d'Entremont.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Medexus Pharmaceuticals Inc named herein, including the promotion by the Company of Medexus Pharmaceuticals Inc in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE